BCDA
BioCardia, Inc. Common StockstockNASDAQ
we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.93 | 2026-11-10 | -17.47% | 1.254 |
| 1M | 0.92 | 2026-10-16 | -16.56% | 1.308 |
| 3M | 0.94 | 2026-08-17 | -18.33% | 0.612 |
| 6M | 0.90 | 2026-05-18 | -14.71% | 0.141 |
| 1Y | 1.22 | 2025-11-17 | -37.07% | 0.511 |
| 2Y | 2.05 | 2024-11-18 | -62.55% | — |
| 5Y | 34.80 | 2021-11-17 | -97.79% | 0.755 |
BioCardia, Inc. Common Stock (NASDAQ:BCDA) stock price today is $0.77, and today's volume is 40,560. BCDA is down 2.835% today. The 30 day average volume is 119,958. BCDA market cap is $11.62M with 15.14M shares outstanding.